Llysergide D-tartrate Phase III Trial
This is a US news story, published by Home, that relates primarily to MindMed news.
US news
For more US news, you can click here:
more US newsmental health treatments news
For more mental health treatments news, you can click here:
more mental health treatments newsHome news
For more news from Home, you can click here:
more news from HomeAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like mental health treatments news, you might also like this article about
Mind Medicine. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest label treatment news, dosage news, mental health treatments news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
MindMedHome
•Health
Health
MindMed doses first subject in Phase III Panorama study of GAD tablet

86% Informative
MindMed has dosed the first subject in the Phase III Panorama study of a proprietary form of lysergide D-tartrate (LSD), MM120 orally disintegrating tablets (ODT) The 52-week trial will take place across Europe and the US , aiming to enrol approximately 250 subjects.
VR Score
87
Informative language
85
Neutral language
82
Article tone
formal
Language
English
Language complexity
56
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
3
Source diversity
1
Affiliate links
no affiliate links